A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

January 6, 2015

Primary Completion Date

March 5, 2016

Study Completion Date

March 5, 2016

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

GSK2982772 solution

Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg

DRUG

GSK2982772 capsule

Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg

DRUG

Placebo solution

Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg

DRUG

Placebo capsule

Size 00 White Opaque capsule containing Placebo as white to almost white solid

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Clinical Unit at Cambridge (Addenbrooks)

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT02302404 - A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects | Biotech Hunter | Biotech Hunter